<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832415</url>
  </required_header>
  <id_info>
    <org_study_id>ENCOURAGE (GINECO-OV123)</org_study_id>
    <nct_id>NCT01832415</nct_id>
  </id_info>
  <brief_title>First Line Ovarian Cancer Treatment - Cohort Study</brief_title>
  <acronym>ENCOURAGE</acronym>
  <official_title>Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The French cooperative group GINECO proposes to implement an observational study to describe
      a real situation, in daily practice tolerance and methods of administration of bevacizumab
      (Avastin ®)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian
      tube or primary peritoneal or witch it was decided to initiate a process comprising of
      Bevacizumab (Avastin ®) in first-line therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Safety according to CTCAE v4.0 criteria</measure>
    <time_frame>Patient will be followed dureing 36 months</time_frame>
    <description>To assess patient safety and the tolerance of bevacizumab andministered regarding the daily practice of the oncologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Patient will be followed during 36 months</time_frame>
    <description>• Evaluate the efficacy of bevacizumab (Avastin ®) in terms of progression-free survival (PFS) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment at relapse</measure>
    <time_frame>Patient will be followed during 36 months</time_frame>
    <description>Evaluate the efficacy of the treatment that will be administered at the disease relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of the population registered</measure>
    <time_frame>At registration</time_frame>
    <description>Discribe the population that will be registered to make correlation with the safety and efficacy measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication and cons indication of bevacizumab in clinical practice</measure>
    <time_frame>At registration</time_frame>
    <description>Discribe the reason why patient receive or not bevacizumab in first line of ovarian cancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of monitoring practices of bevacizumab</measure>
    <time_frame>The patients will be followed during 36 months</time_frame>
    <description>Discribe the method that are used during a treatment by bevacizumab in the daily practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the modality of use of bevacizumab</measure>
    <time_frame>The patients will be followed during 36 months</time_frame>
    <description>Discribe how bevacizumab is administered in the daily practice</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Use of bevacizumab (Avastin ®) - First-line ovarian cancer</arm_group_label>
    <description>Patient receiving bevacizumab in ovarian cancer first line treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Observation of bevacizumab administration in first line ovarian cancer treatment</description>
    <arm_group_label>Use of bevacizumab (Avastin ®) - First-line ovarian cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        • Patients with epithelial ovarian cancer, fallopian tube or peritoneal with treatment
        receiving Bevacizumab (Avastin ®) in first-line therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years and over,

          -  Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will
             receive bevacizumab (Avastin ®) in first-line therapy

          -  Patients should be informed of the study orally and should not have any objection
             their data to be processed.

        Exclusion Criteria:

          -  Patient participation in a clinical trial

          -  Patient non-affiliated to a social security scheme.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique BERTON-RIGAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO de l'Ouest, Site René Gauducheau - Saint-Herblain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Fréjus</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Valdegour</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcagy-Gineco</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>St Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First line treatment</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Avastin</keyword>
  <keyword>fallopian tube or primary peritoneal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

